Search

Your search keyword '"Rheumatoid factor -- Technology application"' showing total 48 results
Start Over Descriptor "Rheumatoid factor -- Technology application"
48 results on '"Rheumatoid factor -- Technology application"'

1. Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

Subjects
Rheumatoid factor -- Technology application, Antiarthritic agents -- Intellectual property -- Technology application, Nanoparticles -- Technology application, Cancer -- Care and treatment -- Technology application, Arthritis -- Technology application, RNA -- Technology application, Technology application, Banking, finance and accounting industries, Business
Abstract

Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA [...]

Published
2024

2. SecondWave Systems Announces Professor Paul Peter Tak as New Advisory Board Member and Secures $3M Additional Financing to Accelerate Development of Novel Ultrasound-Based Anti-Inflammatory Therapy

Subjects
United States. Defense Advanced Research Projects Agency -- Technology application, Medical centers -- Technology application, Rheumatoid factor -- Technology application, Antiarthritic agents -- Technology application, Arthritis -- Drug therapy, Anti-inflammatory drugs -- Technology application, Technology application, Business, Business, international
Abstract

New funding from ARPA-H, in partnership with DARPA, directly supports development of next-generation technology for at-home treatment of rheumatoid arthritis and other inflammatory disorders ST. PAUL, Minn. -- SecondWave Systems, [...]

Published
2024

3. SetPoint: First Patient Enrolled in Stage 2 of Pivotal Study of Medical's Pioneering Technology for the Treatment of Rheumatoid Arthritis

Subjects
Rheumatoid factor -- Technology application, Antirheumatic agents -- Technology application, Arthritis -- Drug therapy, Drug approval -- Technology application, Technology application, Arts and entertainment industries
Abstract

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, reported the enrollment of the first participant in Stage 2 of the company's RESET-RA pivotal study. The [...]

Published
2022

4. Altamira Therapeutics initiates development program for RA therapeutics

Subjects
Rheumatoid factor -- Technology application, RNA -- Technology application, Pancreatic cancer -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

Altamira Therapeutics announced the initiation of a development program based on its proprietary OligoPhore delivery platform and siRNA targeting NF-B, for a novel generation of rheumatoid arthritis therapeutics. The Company [...]

Published
2022

6. Supply Erba Rheumatoid Factor System Pack Kit With Calibrator Boq Title Erba Mannheim Fully Automated Biochemistry Analyser System Pack Rf Kit Qty : 9

Subjects
Biochemistry -- Technology application, Rheumatoid factor -- Technology application, Technology application, Business, international
Abstract

Tenders are invited for Supply erba rheumatoid factor system pack kit with calibrator boq title erba mannheim fully automated biochemistry analyser system pack rf kit Qty : 9 Tender Category [...]

Published
2022

7. First Patient Enrolled in Stage 2 of Pivotal Study of SetPoint Medical's Pioneering Technology for the Treatment of Rheumatoid Arthritis

Subjects
Rheumatoid factor -- Technology application, Antirheumatic agents -- Technology application, Arthritis -- Drug therapy, Drug approval -- Technology application, Technology application, General interest, News, opinion and commentary
Abstract

VALENCIA: SETPOINT MEDICAL has issued the following news release: SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced the enrollment of the first participant in [...]

Published
2022

8. First Patient Enrolled in Stage 2 of Pivotal Study of SetPoint Medical's Pioneering Technology for the Treatment of Rheumatoid Arthritis

Subjects
Rheumatoid factor -- Technology application, Antirheumatic agents -- Technology application, Arthritis -- Drug therapy, Drug approval -- Technology application, Technology application, Business, Business, international
Abstract

Results From RESET-RA Study Will Support FDA Submission for Approval of This Promising Treatment Approach for RA VALENCIA, Calif. -- SetPoint Medical, a clinical-stage healthcare company dedicated to patients with [...]

Published
2022

9. Recent Findings from University of Zagreb School of Medicine Has Provided New Data on Rheumatoid Arthritis (Combined manual and automated immunophenotypisation identified disease-specific peripheral blood immune subpopulations in rheumatoid ...)

Subjects
Technology application, Research, Physical fitness -- Technology application, Rheumatoid factor -- Technology application, Medical research -- Technology application, Psoriasis -- Research -- Technology application, Arthritis -- Research -- Technology application, Antiarthritic agents -- Research -- Technology application, T cells -- Technology application, Criminal investigation, Citrus, Ankylosing spondylitis, Psoriatic arthritis, Obesity, Autoimmune diseases, Spondylitis, Editors
Abstract

2019 DEC 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Autoimmune Diseases and Conditions - Rheumatoid Arthritis. [...]

Published
2019

10. SetPoint: First Patient Enrolled in Stage 2 of Pivotal Study of Medical's Pioneering Technology for the Treatment of Rheumatoid Arthritis

Subjects
Rheumatoid factor -- Technology application, Antirheumatic agents -- Technology application, Arthritis -- Drug therapy, Drug approval -- Technology application, Technology application, Business, Business, international, Telecommunications industry
Abstract

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, reported the enrollment of the first participant in Stage 2 of the company's RESET-RA pivotal study. The [...]

Published
2022

11. First Patient Enrolled in Stage 2 of Pivotal Study of SetPoint Medical's Pioneering Technology for the Treatment of Rheumatoid Arthritis

Subjects
Rheumatoid factor -- Technology application, Antirheumatic agents -- Technology application, Arthritis -- Drug therapy, Drug approval -- Technology application, Technology application, Chemistry
Abstract

M2 PHARMA-October 12, 2022-First Patient Enrolled in Stage 2 of Pivotal Study of SetPoint Medical's Pioneering Technology for the Treatment of Rheumatoid Arthritis (C)2022 M2 COMMUNICATIONS - US-based clinical-stage healthcare [...]

Published
2022

12. How A.I. Steered Doctors Toward a Possible Coronavirus Treatment

Author

Metz, Cade

Subjects
Eli Lilly and Co. -- Technology application, Coronavirus infections -- Technology application, Rheumatoid factor -- Technology application, Antiarthritic agents -- Technology application, Arthritis -- Technology application, Coronaviruses -- Technology application, Pharmaceutical industry -- Technology application, Technology application, General interest
Abstract

Byline: Cade Metz Specialists at the London start-up BenevolentAI helped identify the arthritis drug baricitinib, which is now part of a clinical trial. In late January, researchers at BenevolentAI, an [...]

Published
2020

14. Southwest Jiaotong University Researchers Release New Data on Rheumatoid Arthritis (Targeting the resolution pathway of inflammation using Ac2-26 peptide-loaded PEGylated lipid nanoparticles for the remission of rheumatoid arthritis)

Subjects
Technology application, Rheumatoid factor -- Technology application, Inflammation -- Technology application, Peptides -- Technology application, Arthritis -- Technology application, Antiarthritic agents -- Technology application
Abstract

2021 OCT 29 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on rheumatoid arthritis is now available. According to news reporting [...]

Published
2021

15. DREAM Challenge to automate assessment of radiographic damage from rheumatoid arthritis

Subjects
Bristol-Myers Squibb Co. -- Technology application, Rheumatoid factor -- Technology application, Machine learning -- Technology application, Pharmaceutical industry -- Technology application, Arthritis -- Diagnosis -- Technology application, Scientists, Health, Computational biology, Automation, Technology application, News, opinion and commentary, Sports and fitness
Abstract

S. Louis Bridges Jr., M.D., Ph.D., and his team have been awarded $100,000 by the National Institutes of Health National Center for Data to Health Awards Program and $200,000 by [...]

Published
2019

16. Warszawski Uniwersytet Medyczny Researchers Detail Research in Rheumatoid Arthritis (Methotrexate - pharmacological properties and its application in pharmacotherapy)

Subjects
Drug therapy, Technology application, Rheumatoid factor -- Technology application, Methotrexate -- Technology application, Arthritis -- Drug therapy
Abstract

2020 SEP 25 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on rheumatoid arthritis have been published. According to news reporting [...]

Published
2020

17. Studies from Department of Biomedical Engineering Add New Findings in the Area of Rheumatoid Arthritis (Thermography and colour Doppler ultrasound: a potential complementary diagnostic tool in evaluation of rheumatoid arthritis in the knee ...)

Subjects
Technology application, Research, Algorithm, Algorithms -- Technology application, Rheumatoid factor -- Technology application, Biomedical engineering -- Technology application, Medical research -- Technology application, Arthritis -- Research -- Technology application, Antiarthritic agents -- Research -- Technology application, Autoimmune diseases
Abstract

2019 DEC 27 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Autoimmune Diseases and Conditions - Rheumatoid Arthritis. According [...]

Published
2019

18. Investigators from Kaiser Permanente Northern California Have Reported New Data on Antirheumatics (Development of an Algorithm To Detect Methotrexate Wrong Frequency Error Using Computerized Health Care Data)

Subjects
Algorithms -- Technology application, Medical records -- Technology application, Rheumatoid factor -- Technology application, Methotrexate -- Technology application, Health care information services -- Technology application, Health maintenance organizations -- Technology application, Electronic records, Arthritis, Antineoplastic agents, Editors, Algorithm, Technology application, Computers, News, opinion and commentary, Kaiser Permanente -- Technology application
Abstract

2019 SEP 11 (VerticalNews) -- By a News Reporter-Staff News Editor at Computer Weekly News -- Investigators discuss new findings in Drugs and Therapies - Antirheumatics. According to news reporting [...]

Published
2019

19. United States : Janssen Submits Two Applications To FDA Seeking Approval Of Simponi Aria (Golimumab) For The Treatment Of Active Psoriatic Arthritis And Active Ankylosing Spondylitis

Subjects
United States. Food and Drug Administration -- Technology application, Ankylosing spondylitis -- Care and treatment -- Technology application, Tumor necrosis factor -- Technology application, Rheumatoid factor -- Technology application, Psoriatic arthritis -- Care and treatment -- Technology application, Drug approval -- Technology application, Antiarthritic agents -- Technology application, Technology application, Business, international, Simponi (Medication)
Abstract

Janssen Biotech, Inc. (Janssen) announced today the submission of two Supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA (golimumab) for [...]

Published
2016

20. Janssen Submits Two Applications To FDA Seeking Approval Of SIMPONI ARIA (golimumab) For The Treatment Of Active Psoriatic Arthritis And Active Ankylosing Spondylitis

Subjects
United States. Food and Drug Administration -- Technology application, Ankylosing spondylitis -- Care and treatment -- Technology application, Tumor necrosis factor -- Technology application, Rheumatoid factor -- Technology application, Psoriatic arthritis -- Care and treatment -- Technology application, Drug approval -- Technology application, Antiarthritic agents -- Technology application, Adults -- Technology application, Technology application, Business, News, opinion and commentary, Simponi (Medication)
Abstract

HORSHAM, Pa., Dec. 20, 2016 /PRNewswire/ -- Janssen Biotech, Inc. (Janssen) announced today the submission of two Supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) [...]

Published
2016

21. Doctors put arthritic youth back on feet; healing touch Hip replacement surgery using new tech in Nanavati Hospital works wonders

Subjects
Rheumatoid factor -- Technology application, Physicians -- Technology application, Arthritis -- Technology application, Teenagers -- Technology application, Youth -- Technology application, Surgery -- Technology application, Technology application, News, opinion and commentary
Abstract

Byline: dna correspondent healing touch Hip replacement surgery using new tech in Nanavati Hospital works wonders Nanavati hospital recently helped a 22-year-old youth get back on his feet after rheumatoid [...]

Published
2014

22. Arthritic youth back on feet, courtesy Nanavati doctors; healing touch Hip replacement surgery using new tech works wonders

Subjects
Rheumatoid factor -- Technology application, Physicians -- Technology application, Arthritis -- Technology application, Teenagers -- Technology application, Youth -- Technology application, Surgery -- Technology application, Technology application, News, opinion and commentary
Abstract

Byline: dna correspondent healing touch Hip replacement surgery using new tech works wonders Nanavati hospital recently helped a 22-year-old youth get back on his feet after rheumatoid arthritis left him [...]

Published
2014

23. Vium Brings Out Peer-Reviewed Publication for Its Digital Vivarium Technology

Subjects
Rheumatoid factor -- Technology application, Arthritis -- Technology application, Technology application, Business, Business, international, Telecommunications industry
Abstract

Vium reported the publication of a peer reviewed paper in the journal Frontiers in Pharmacology. According to a media release, the article titled 'Development of the Digital Arthritis Index, a [...]

Published
2017

24. Parvus Therapeutics' Nanotechnology Treatment Reprograms Immune Cells to Reverse Autoimmune Disease, as Published in Nature

Subjects
Rheumatoid factor -- Technology application, Autoimmunity -- Technology application, Nanotechnology -- Technology application, Technology application, Business, Business, international
Abstract

- Nanotechnology Approach Restores Glucose Regulation and Motor Function in In Vivo Preclinical Models of Diabetes and Multiple Sclerosis, Respectively; Joint Swelling and Destruction Resolved in In Vivo Model of [...]

Published
2016

25. Studies from Central Hospital Add New Findings in the Area of Rheumatoid Arthritis (Automated immunoassays for the autoantibodies to carbamylated or citrullinated telopeptides of type I and II collagens)

Subjects
Technology application, Research, Rheumatoid factor -- Technology application, Autoimmunity -- Technology application, Arthritis -- Research -- Technology application
Abstract

2015 AUG 28 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on Autoimmune Diseases and Disorders is the subject of a report. [...]

Published
2015

26. Study Results from U. Snekhalatha et al Provide New Insights into Rheumatoid Arthritis (Automated hand thermal image segmentation and feature extraction in the evaluation of rheumatoid arthritis)

Subjects
Diagnosis, Technology application, Image processing -- Technology application, Rheumatoid factor -- Technology application, Arthritis -- Diagnosis -- Technology application
Abstract

By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Autoimmune Diseases and Disorders. According to news reporting out of Tamil Nadu, India, [...]

Published
2015

27. Singulex's Assay for Cardiovascular Risk Assessment Highlighted in Two Presentations at AHA 2013 Scientific Sessions

Subjects
Rheumatoid factor -- Technology application, Risk assessment -- Technology application, Cardiovascular diseases -- Diagnosis -- Technology application, Cardiac patients -- Technology application, Technology application, Business, Business, international
Abstract

-- Cardiac troponin-I shown to be predictor of cardiovascular risk in two patient populations when measured using Singulex's ultrasensitive Single Molecule Counting Technology -- ALAMEDA, Calif. -- Singulex, Inc., the [...]

Published
2013

28. The Future of Amyloid Detection

Subjects
Rheumatoid factor -- Technology application, Amyloid beta-protein -- Technology application, Alzheimer's disease -- Technology application, Peptides -- Technology application, Technology application, Business, general
Abstract

Knoxville, Tennessee (PRWEB) November 07, 2013 Solex LLC. has licensed a peptide-based technology for the diagnostic visualization of amyloid burden in patients with amyloid-related diseases by using molecular imaging techniques. [...]

Published
2013

29. Immune Response BioPharma files for Orphan Designation of Ravax for Juvenile RA

Subjects
Biological products industry -- Technology application, T cells -- Technology application, Rheumatoid factor -- Technology application, Rheumatoid arthritis -- Technology application, Technology application, Business, Chemicals, plastics and rubber industries
Abstract

Immune Response BioPharma Inc (IRBP) on 23 Oct 2012 files for Orphan Designation of Blockbuster Drug Ravax for expanded use into the rare disease Juvenile Rheumatoid Arthritis (RA). Juvenile RA [...]

Published
2012

30. Benitec Biopharma and Medistem Technologies Successfully Combined in Preclinical Stem Cell Therapy for Rheumatoid Arthritis

Subjects
Biological products industry -- Intellectual property -- Technology application, Rheumatoid factor -- Technology application, Genes -- Technology application, Stem cells -- Technology application -- Transplantation, Antirheumatic agents -- Technology application, Dendritic cells -- Technology application, Genetic engineering -- Technology application, Rheumatoid arthritis -- Care and treatment -- Technology application, Pharmaceutical industry -- Intellectual property -- Technology application, Company business management, Technology application, Business, Business, international, News, opinion and commentary
Abstract

Byline: SYDNEY, AUSTRALIA and SAN DIEGO, CA, Feb 06, 2012 (MARKETWIRE via COMTEX) -- Benitec Biopharma (ASX: BLT) and Medistem (PINKSHEETS: MEDS) announced today the successful treatment of rheumatoid arthritis [...]

Published
2012

31. MorphoSys Presents Comprehensive Pipeline and Technology Update at R&D Day in London

Subjects
MorphoSys AG -- Technology application, Biological products industry -- Technology application, Rheumatoid factor -- Technology application, Biological products -- Technology application, Multiple sclerosis -- Technology application, Biotechnology industry -- Technology application, Clinical trials -- Technology application, Rheumatoid arthritis -- Technology application, Pharmaceutical industry -- Technology application, Technology application, Business, Business, international, News, opinion and commentary
Abstract

Byline: MARTINSRIED, GERMANY and MUNCHEN, GERMANY, Nov 25, 2010 (MARKETWIRE via COMTEX) -- MorphoSys AG / MorphoSys Presents Comprehensive Pipeline and Technology Update at R&D Day in London Processed and [...]

Published
2010

32. Developer Says CEL-SCI's L.E.A.P.S. Technology Has Extensive Applications

Subjects
Technology application, CEL-SCI Corp. -- Media coverage -- Technology application, Biological products industry -- Technology application, Rheumatoid factor -- Technology application
Abstract

LOS ANGELES, CA, Oct 19, 2009 (MARKETWIRE via COMTEX) -- BioMedReports.com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of […]

Published
2009

33. Study Results from University of British Columbia Provide New Insights into Rheumatoid Arthritis

Subjects
University of British Columbia -- Technology application, Technology application, Research, Rheumatoid factor -- Technology application, Arthritis -- Research -- Technology application
Abstract

By a News Reporter-Staff News Editor at Health & Medicine Week -- Fresh data on Autoimmune Diseases are presented in a new report. According to news reporting originating in Vancouver, [...]

Published
2014

34. Findings on Rheumatoid Arthritis Detailed by A. Pfeil and Co-Authors

Subjects
Technology application, Rheumatoid factor -- Technology application, Arthritis -- Technology application
Abstract

By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Autoimmune Diseases. According to news reporting originating in Gera, Germany, by NewsRx journalists, research stated, [...]

Published
2013

35. Benitec Biopharma and Medistem Technologies Successfully Combined in Preclinical Stem Cell Therapy for Rheumatoid Arthritis

Subjects
Technology application, Care and treatment, Genetic engineering -- Technology application, Antirheumatic agents -- Technology application, Rheumatoid arthritis -- Care and treatment -- Technology application, Rheumatoid factor -- Technology application, Stem cells -- Technology application, Arthritis -- Care and treatment -- Technology application, Biological products industry -- Technology application, Antiarthritic agents -- Technology application, Stem cell transplantation -- Technology application, Stem cells -- Technology application -- Transplantation
Abstract

Benitec Biopharma (ASX: BLT) and Medistem (PINKSHEETS: MEDS) announced the successful treatment of rheumatoid arthritis in preclinical models using Benitec Biopharma's patented gene silencing technology applied to stem cell-derived immune [...]

Published
2012

36. Benitec Biopharma and Medisterm Technologies combine in preclinical stem cell therapy for rheumatoid arthritis

Subjects
Biological products industry -- Technology application, Rheumatoid factor -- Technology application, Stem cells -- Technology application -- Transplantation, Antirheumatic agents -- Technology application, Rheumatoid arthritis -- Care and treatment -- Technology application, Technology application, Chemistry
Abstract

M2 PHARMA-February 7, 2012-Benitec Biopharma and Medisterm Technologies combine in preclinical stem cell therapy for rheumatoid arthritis(C)2012 M2 COMMUNICATIONS Medistem (PINKSHEETS:MEDS) on Monday announced that with Benitec Biopharma (ASX:BLT) it [...]

Published
2012

37. Benitec Biopharma, Medistem Technologies combine preclinical stem cell therapy for rheumatoid arthritis

Subjects
Technology application, Care and treatment, Antirheumatic agents -- Technology application, Rheumatoid arthritis -- Care and treatment -- Technology application, Rheumatoid factor -- Technology application, Stem cells -- Technology application, Arthritis -- Care and treatment -- Technology application, Biological products industry -- Technology application, Stem cell transplantation -- Technology application, Stem cells -- Technology application -- Transplantation
Abstract

Benetic Biopharma, Sydney, Australia and Medistem Technologies, San Diego, CA, announced they successfully treated rheumatoid arthritis in preclinical models using Benetic's patented gene silencing technology applied to stem cell-derived immune [...]

Published
2012

38. Antares Pharma Granted New U.S. Patent Covering VIBEX™ Injector Technology

Subjects
Antares Pharma Inc. -- Intellectual property -- Technology application, Technology application, Intellectual property, Patent/copyright issue, Rheumatoid arthritis -- Technology application, Antirheumatic agents -- Technology application, Rheumatoid factor -- Technology application, Medical equipment industry -- Intellectual property -- Technology application, Patents -- Technology application, Pharmaceutical industry -- Intellectual property -- Technology application, Medical test kit industry -- Intellectual property -- Technology application, Medical equipment and supplies industry -- Intellectual property -- Technology application
Abstract

Antares Pharma, Inc. (NYSE Amex:AIS) announced that U.S. Patent number 8,021,335 has been granted by United States Patent and Trademark Office (USPTO), covering technology used in the Company's VIBEX™ platform [...]

Published
2011

39. FDA Clears SQI's Automated SQiDworks Diagnostics Platform and IgXPLEX Rheumatoid Arthritis Assay for Sale in the United States

Subjects
Technology application, Rheumatoid arthritis -- Technology application, Rheumatoid factor -- Technology application
Abstract

SQI Diagnostics Inc. (TSX-V: SQD), a medical systems automation company focused on evolving laboratory-based biomarker testing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's automated [...]

Published
2009

40. Peptide autoantibodies measured by automated enzyme immunoassay

Subjects
Technology application, Immunoassay enzymes -- Technology application, Rheumatoid arthritis -- Technology application, Enzyme-linked immunosorbent assay -- Technology application, Autoimmunity -- Technology application, Rheumatoid factor -- Technology application, Peptides -- Technology application, Biological markers -- Technology application
Abstract

Peptide autoantibodies could be measured by an automated enzyme immunoassay. 'Autoantibodies against cyclic citrullinated peptide (anti-CCP) are considered to be a sensitive and specific marker for rheumatoid arthritis (RA). This [...]

Published
2005

41. Peptide autoantibodies measured by automated enzyme immunoassay

Subjects
Technology application, Immunoassay enzymes -- Technology application, Rheumatoid arthritis -- Technology application, Enzyme-linked immunosorbent assay -- Technology application, Autoimmunity -- Technology application, Rheumatoid factor -- Technology application, Peptides -- Technology application, Biological markers -- Technology application
Abstract

Peptide autoantibodies could be measured by an automated enzyme immunoassay. 'Autoantibodies against cyclic citrullinated peptide (anti-CCP) are considered to be a sensitive and specific marker for rheumatoid arthritis (RA). This [...]

Published
2005

42. Peptide autoantibodies measured by automated enzyme immunoassay

Subjects
Technology application, Immunoassay enzymes -- Technology application, Rheumatoid arthritis -- Technology application, Enzyme-linked immunosorbent assay -- Technology application, Rheumatoid factor -- Technology application, Autoimmunity -- Technology application, Peptides -- Technology application, Biological markers -- Technology application
Abstract

Peptide autoantibodies could be measured by an automated enzyme immunoassay. 'Autoantibodies against cyclic citrullinated peptide (anti-CCP) are considered to be a sensitive and specific marker for rheumatoid arthritis (RA). This [...]

Published
2005

43. Entelos to co-develop rheumatoid arthritis therapies

Subjects
Entelos Inc. -- Technology application, Technology application, Rheumatoid arthritis -- Technology application, Rheumatoid factor -- Technology application, Pharmaceutical industry -- Technology application
Abstract

Entelos, Inc., a company focused on biosimulation technologies for pharmaceutical research and development, and Organon, an international pharmaceutical company that is developing immune and anti-inflammatory therapies, announced they would extend [...]

Published
2005

44. Entelos to co-develop rheumatoid arthritis therapies

Subjects
Entelos Inc. -- Alliances and partnerships -- Technology application, Alliances and partnerships, Technology application, Rheumatoid arthritis -- Technology application, Rheumatoid factor -- Technology application, Pharmaceutical industry -- Alliances and partnerships -- Technology application
Abstract

Entelos, Inc., a company focused on biosimulation technologies for pharmaceutical research and development, and Organon, an international pharmaceutical company that is developing immune and anti-inflammatory therapies, announced they would extend [...]

Published
2005

45. Entelos to co-develop rheumatoid arthritis therapies

Subjects
Entelos Inc. -- Alliances and partnerships -- Technology application, Alliances and partnerships, Technology application, Rheumatoid arthritis -- Technology application, Rheumatoid factor -- Technology application, Pharmaceutical industry -- Alliances and partnerships -- Technology application
Abstract

Entelos, Inc., a company focused on biosimulation technologies for pharmaceutical research and development, and Organon, an international pharmaceutical company that is developing immune and anti-inflammatory therapies, announced they would extend [...]

Published
2005

46. Genomics company details versatility of protein labeling technology

Subjects
Agilix Corp. -- Technology application, Technology application, Genetic research -- Technology application, Rheumatoid factor -- Technology application, Labelers (Machinery) -- Technology application, Biotechnology industries -- Technology application, Biotechnology industry -- Technology application, Labeling-machines -- Technology application
Abstract

Agilix Corporation presented data showing the versatility and analytical power of its i-PROT technology for the identification and validation of biomarkers in patients with rheumatoid arthritis at the Cambridge Healthtech [...]

Published
2005

47. Genomics company details versatility of protein labeling technology

Subjects
Agilix Corp. -- Technology application, Technology application, Genetic research -- Technology application, Rheumatoid factor -- Technology application, Labelers (Machinery) -- Technology application, Biotechnology industries -- Technology application, Biotechnology industry -- Technology application, Labeling-machines -- Technology application
Abstract

Agilix Corporation presented data showing the versatility and analytical power of its i-PROT technology for the identification and validation of biomarkers in patients with rheumatoid arthritis at the Cambridge Healthtech [...]

Published
2005

48. Genomics company details versatility of protein labeling technology

Subjects
Agilix Corp. -- Technology application, Technology application, Genetic research -- Technology application, Rheumatoid factor -- Technology application, Labelers (Machinery) -- Technology application, Biotechnology industries -- Technology application, Biotechnology industry -- Technology application, Labeling-machines -- Technology application
Abstract

Agilix Corporation presented data showing the versatility and analytical power of its i-PROT technology for the identification and validation of biomarkers in patients with rheumatoid arthritis at the Cambridge Healthtech [...]

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results